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1. Introduction 
Glucagon secreted from pancreatic ┙-cells plays central roles for counteracting 
hypoglycemia by modulating hepatic glucose metabolism (Gromada et al., 2007). In 
addition, glucagon also contributes to the maintenance of glucose homeostasis together with 
insulin from ┚-cells. During hyperglycemia such as post-prandial state, insulin secretion 
from ┚-cells is stimulated while glucagon secretion from ┙-cells is suppressed, leading to a 
lowering of blood glucose levels due to enhanced hepatic- and adipo- glucose uptake and 
suppressed hepatic glucose output. In contrast, in hypoglycemia such as starvation, 
glucagon secretion is promoted while insulin secretion is reduced, causing elevated blood 
glucose levels via the effects of glucagon, including enhanced hepatic glucose output and 
breakdown of lipids and proteins to provide glucose that is critical to the central nervous 
system. Thus, both glucagon and insulin are pivotal in systemic energy homeostasis, and the 
balance between these two hormones determines the metabolic state of various organs in 
response to changes in energy status. 
In both type 1 and type 2 diabetes, both of which exhibit a global increase in incidence, an 
imbalance between the two hormones appears to significantly impact glucose homeostasis 
(Unger, 1978). Insufficient insulin secretion and systemic insulin resistance both contribute 
to hyperglycemia due to quantitative and qualitative insulin shortage. In addition, abnormal 
elevations in circulating glucagon, due to lack of normal suppression mechanisms, worsens 
the hyperglycemia via enhanced hepatic glucose output. On the other hand, in patients 
undergoing treatment for diabetes, an increased incidence of hypoglycemia likely occurs 
due to a poor glucagon response. Whether this poor glucagon response is a consequence of 
impaired effects of insulin due to repeated treatment with exogenous insulin or other factors 
is not fully understood (Gerich et al., 1973). Therefore, diabetes can be recognized as “state 
where adequate hormones cannot work appropriately” when intra-islet hormone balance is 
focused on. These observations have prompted consideration of glucagon in the overall 
therapeutic approach to treat patients with both type 1 and type 2 diabetes. Furthermore, 
novel therapeutic approaches targeting Glucagon-like peptide (GLP)-1 action in ┙-cells 
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(GLP-1 analogues and DPP-4 inhibitors) are also being considered given the potential for 
GLP-1 to have direct suppressive effects on ┙-cells, thus these enabled comprehensive 
control of islet hormone balance including improvement of both insulin and glucagon 
secretion. 
Therefore, it becomes more important to understand the underlying molecular mechanisms 
for the regulation of glucagon secretion to apply new therapeutic approaches to diabetes 
targeting ┙-cell dysfunction. 
2. Functions of glucagon 
2.1 Functions of glucagon 
Glucagon is a 29 amino acid peptide hormone, secreted by pancreatic ┙-cells mainly in 
hypoglycemic state, and exerts multiple biological effects on a wide range of organs 
(Kawamori et al., 2010). Glucagon has important functions in vivo for sustaining appropriate 
blood glucose level. In physiological states, glucagon is released into the bloodstream in 
response to hypoglycemia to oppose the action of insulin in peripheral tissues, and works as 
a counter-regulatory hormone to restore normoglycemia. Secreted glucagon works 
predominantly on the liver, and promotes hepatic gluconeogenesis, glycogenolysis, and 
simultaneously inhibits glycolysis and glycogenesis (Exton et al., 1966; Unger and Orci, 
1977), thus contributing to restoring glucose homeostasis by counteracting the action of 
insulin. In contrast, insulin suppresses hepatic glucose output while enhancing hepatic 
glucose uptake and glycogenesis, indicating that a balance between these two hormones ath 
the hepatocyte determines hepatic glucose metabolism, thus systemic glycemic homeostasis. 
In addition to countering hypoglycemia and opposing the effects of insulin in the liver, 
glucagon has impacts the function of several metabolic organs together favoring the 
maintenance of glucose homeostasis. For example, in the adipose tissue, glucagon enhances 
lipid decomposition, while, in contrast, the lack of detectable glucagon receptors in skeletal 
muscle indicates glucagon has little effect in regulating systemic glucose metabolism by 
acting on skeletal muscle (Christophe, 1996). Glucagon can also stimulate insulin secretion 
from pancreatic ┚-cells (Scheen et al., 1996) and indirectly impact hepatic glucose output. 
Taken together, these actions indicate an important role for glucagon in maintaining glucose 
homeostasis. 
2.2 Molecular mechanism underlying glucagon action 
The glucagon receptor is a G-protein (Gs/Gq) coupled type receptor (Jelinek et al., 1993) and 
is widely expressed in insulin target organs, such as liver, adipose, ┚-cells and brain, with 
the exception of skeletal muscle (Burcelin et al., 1995). Following binding and 
conformational changes of the receptor the activation of Gs leads to recruitment of adenylate 
cyclase to the cellular membrane, causing an increase in intracellular cyclic adenosine 
monophosphate (cAMP) levels and subsequent activation of protein kinase A (PKA) 
(Weinstein et al., 2001). On the other hand, activation of Gq induces activation of 
phospholipase C, upregulation of inositol 1,4,5-triphosphate, and the subsequent release of 
intracellular calcium (Ca2+) (Wakelam et al., 1986). The action of glucagon is relatively 
complex and involves the coordinate regulation of transcription factors and signal 
transduction networks which converge to regulate amino acid, lipid and carbohydrate 
metabolism. For example, in the liver, elevated PKA activity activates various downstream 
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targets leading to the suppression of glycolysis and glycogenesis, and the enhancement of 
gluconeogenesis and glycogenolysis (Jiang and Zhang, 2003). In islet cells, the elevation of 
cAMP by glucagon has been reported to stimulate insulin and glucagon secretion from ┚- 
and ┙-cells respectively (Huypens et al., 2000; Ma et al., 2005) by PKA dependent and 
independent mechanisms. Upregulation of cAMP activates cAMP-regulated guanine 
nucleotide exchange factors (cAMPGEFs / Epac), which modulates intracellular Ca2+-ion 
mobilization, enhancing exocytosis (Holz et al., 2006; Ma et al., 2005). 
2.3 Anatomical characteristics of pancreatic islets and α-cells 
Pancreatic islets possess unique anatomical characteristics and are composed of five 
different endocrine cell types distributed as islands randomly within the exocrine pancreas. 
Among these five endocrine cells in islets, the α-cells account for approximately 20% of islet 
cells. 
In adult rodents, ┚-cells are restricted mostly to the islet core, while ┙-cells, somatostatin-
secreting ├-cells, pancreatic polypeptide-secreting PP-cells, and ghrelin-secreting ┝-cells, are 
scattered along the periphery of the islet and surrounding ┚-cells. It is likely that this 
distribution and arrangement of different islet cell types is teleologically important for 
physiological regulation between the cells since the blood flows from the center of the islets 
toward periphery; i.e.┚-cells to non-┚-cells in the islet microcirculation system (Bonner-Weir 
and Orci, 1982; Stagner and Samols, 1986), suggesting that secreted insulin regulates 
hormone secretion from other islet cell types. This architecture is typically preserved in 
rodent islets, while in humans, non-┚-cells are often observed both at the periphery and also 
seemingly in clusters within the center of islets (Cabrera et al., 2006). This implies several 
possibilities; 1) rodent cellular hierarchy in the islets does not apply to human islets, or 2) 
human islets consist of several clover-leaf like ‘rosettes’, with each rosette resembling the 
basic islet architecture observed in rodent islets (Bonner-Weir and O'Brien, 2008) suggesting 
 
 
Schematic image for the structure of mouse and human islets adapted from the recent 
publication of (Bosco, 2010) (10). 
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the arrangement and interaction of the different cell types in human islets is similar to that 
in rodents. Recent studies report that in large human islets blood vessels penetrate and 
branch inside islets, and ┙-cells located within the core of islets are placed along these 
vessels and surrounded by ┚-cells (Bosco et al.). Thus, according to this report, in human 
islets, ┙-cells which appear to be placed in the islet core are still ‘peripheral’ in the islets 
since blood vessels are usually considered to be placed outside the islets. Given the direction 
of intraislet microcirculation described above, intraislet auto-/paracrine effects between islet 
cells especially from ┚- to non-┚-cells can be applied to human islets. 
2.4 Excessive glucagon secretion in diabetes 
Glucagon plays critical roles in glucose homeostasis largely by regulating hepatic glucose 
metabolism. However, circulating glucagon levels are often elevated in both type 1 and type 
2 diabetes, thus are suggested to contribute to the development of insulin resistance (e.g. 
hepatic insulin resistance) and exacerbation of diabetes (Ahren and Larsson, 2001; Dinneen 
et al., 1995; Larsson and Ahren, 2000; Unger, 1978). In addition, the absence of postprandial 
glucagon suppression in diabetes patients also contributes to postprandial hyperglycemia 
(Mitrakou et al., 1992; Raskin and Unger, 1978; Sherwin et al., 1976). Another potential 
contributor to the excess glucagon levels is a relative increase in ┙-cells compared to -cells 
in pancreatic islets in both type 1 (Orci et al., 1976) and type 2 diabetes (Rahier et al., 1983; 
Yoon et al., 2003). Moreover, in type 1 diabetic islets, an increase in ┙-cell area and number, 
and dysregulated cell-type distribution in islets is due to specific -cell destruction. 
Although the precise mechanism(s) of relative hyperglucagonemia in the diabetic state is 
still obscure, -cell dysfunction is a possible candidate since -cell secretory products, 
including insulin, are known to suppress glucagon secretion (see section 4.1.). Thus altered 
(impaired) -cell function in diabetes can potentially induce inappropriately elevated 
glucagon in hyperglycemic states by impairing the intraislet influence of -cells on glucagon 
regulation (Meier et al., 2006a). 
2.5 Defective glucagon response to hypoglycemia in diabetes 
Diabetes patients (both type 1 and type 2) frequently develop defective counter-regulatory 
responses to hypoglycemia that is associated with reduced or absent glucagon secretory 
responses. A defective glucagon secretory response to hypoglycemia in hyperinsulinemic 
states frequently exacerbates a hypoglycemic attack, and limits intensive glucose control 
by insulin therapy (Amiel et al., 1988; Gerich et al., 1973). Moreover, hypoglycemia 
associated autonomic failure is induced especially in patients with frequent exposure to 
hypoglycemia leading to a worsening phenotype (Cryer, 1994). This defective response to 
hypoglycemia includes sympathoadrenal and neurohormonal responses against 
hypoglycemia such as epinephrine, cortisol and growth hormone that act to decrease 
blood glucose further, finally leading to sudden states of hypoglycemia and hypoglycemia 
unawareness (Amiel et al., 1988; Gerich et al., 1973). How diabetes induces these defective 
responses to hypoglycemia is still under investigation and suggested theories include 
alteration in brain glucose transport and metabolism by frequent exposure to 
hypoglycemia (Criego et al., 2005) and/or defective intraislet -cell effects on ┙-cell 
function, such as the “switch-off” of insulin (Hope et al., 2004; Zhou et al., 2004) or Zinc 
iron (Zhou et al., 2007) (see section 4.). 
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3. Regulation of glucagon secretion 
3.1 Factors involved in glucagon secretion 
The secretion of glucagon from ┙-cells is stimulated in response to hypoglycemia, and 
suppressed by hyperglycemia in vivo. However, the regulation of glucagon secretion is not 
simply determined only by glucose concentration, but is complex and finely controlled by 
additional contribution of neural, hormonal, and intra-islet interactions (Gromada et al., 
2007). While it is still not conclusive whether ┙-cells can directly sense glucose concentration 
outside the cells and subsequently respond in glucagon secretion (section 3.2.), additional 
mechanisms which contribute to the secretion of glucagon have recently been revealed. For 
example, the central nervous system is reported to sense glucose concentration largely 
through the hypothalamus, and to modulate secretion of islet hormones via the autonomic 
nervous system (section 3.3.). In addition, circulating autonomic neurotransmitters such as 
┛-amino-butyric acid (GABA), epinephrine and norepinephrine can stimulate glucagon 
secretion from ┙-cells. As described above, various regulatory mechanisms for the glucagon 
secretion than glucose were uncovered. Among them, it is recently revealed that intra-islet 
regulation by neighboring ┚-cells plays critical roles in the physiology of glucagon secretion 
from ┙-cells (see section 4). 
3.2 Regulation of glucagon secretion by glucose and other nutrients 
The secretion of glucagon from ┙-cells is elevated in response to hypoglycemia and 
suppressed by hyperglycemia in vivo. While some studies suggest a direct suppressive effect 
of glucose on ┙-cell secretory function (Ravier and Rutter, 2005; Vieira et al., 2007), the 
paradoxical stimulation of glucagon secretion by high glucose in isolated islets and ┙-cell 
lines (Franklin et al., 2005; Olsen et al., 2005; Salehi et al., 2006) suggests that additional 
mechanisms contribute to the secretion of glucagon in response to glucose. Also, it is still not 
conclusive whether ┙-cells can directly sense glucose concentration outside the cells then 
respond in glucagon secretion or not. 
Amino acids such as L-arginine are potent stimulators of glucagon secretion (Gerich et al., 
1974). This is physiologically relevant to prevent hypoglycemia after protein intake since 
amino acids also stimulate insulin secretion. L-glutamate is produced, secreted by various 
cell types including neural cells, and acts as a neurotransmitter. In islet ┙-cells, glutamate is 
contained in glucagon secretory vesicles (Yamada et al., 2001). Interestingly, a recent study 
shows that glutamate secreted by ┙-cells functions as an autocrine positive feedback signal 
for glucagon secretion (Cabrera et al., 2008), as ┙-cells express glutamate transporters and 
receptors (Hayashi et al., 2001). Low glucose stimulates glutamate release from ┙-cells, 
which in turn acts on ┙-cells in an autocrine manner leading to membrane depolarization 
and glucagon secretion (Cabrera et al., 2008). 
3.3 Involvement of nervous system and neurotransmitters 
While glycemia might modulate glucagon secretion directly, several reports indicate the 
involvement of the central and/or autonomic nervous systems in the regulation of glucagon 
secretion (Ahren, 2000; Bloom et al., 1978; Evans et al., 2004; Marty et al., 2005). 
Hypoglycemia is a critical condition for body especially since glucose is an essential fuel for 
the central nervous system. Thus in response to hypoglycemia, the nervous response 
immediately triggers various counterregulatory mechanisms to protect the brain from 
energy deprivation, including the stimulation of glucagon secretion. 
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The dense innervations of the islets suggests that both ┙- and ┚-cells are regulated by the 
nervous system (Ahren, 2000). The autonomic nervous system (ANS) transmits stimuli to 
promote glucagon secretion especially under hypoglycemia when blood glucose must be 
increased to supply fuel for the body. The ANS can modulate all islet cells and regulate 
glucagon secretion directly via the parasympathetic pathway or indirectly by pathways that 
can modulate islet paracrine factors (see section 4.) (Ahren, 2000). In addition, circulating 
autonomic neurotransmitters epinephrine and norepinephrine have been reported to 
stimulate glucagon secretion from ┙-cells through adrenergic receptors (Schuit and 
Pipeleers, 1986; Vieira et al., 2004). Glucagon secretion is also modulated by other 
neurotransmitters including GABA (see section 4.2.) and glutamate (see section 3.2.). 
The precise mechanism by which the central nervous system (CNS) senses blood glucose 
and affects glucagon secretion is not fully understood, although several possibilities have 
been suggested. Glucose sensing in the CNS is suggested to be an interaction between 
neurons and glial cells. For example, neurons in the ventro-medial hypothalamus (VMH) 
have been reported to play a role in sensing hypoglycemia in the brain and triggering the 
responses of counter-regulatory hormones to impact hypoglycemia (Borg et al., 1995), 
through AMPK (McCrimmon et al., 2004), K+ATP channels (Evans et al., 2004), and 
corticoptrophin releasing factor receptors (Cheng et al., 2007) in rat models. Moreover, it has 
also been reported that GLUT2 in cerebral astrocytes acts as a central glucose sensor in the 
modulation of glucagon secretion in mice (Marty et al., 2005). 
4. Intra-islet regulation of glucagon secretion 
In addition to glucose, various regulatory mechanisms for glucagon secretion have been 
detected. Among these mechanisms is the emerging concept that intra-islet regulation by 
secretory products from neighboring ┚-cells plays a critical role in determining ┙-cell 
function. This concept is supported, at least in the rodent, by the direction of the intraislet 
microcirculation which occurs from the core to the periphery and implicates ┙-cells as 
potential direct targets of ┚-cell secretory products such as insulin, (Asplin et al., 1981; 
Kawamori et al., 2009; Maruyama et al., 1984; Weir et al., 1976), GABA (Rorsman et al., 1989; 
Xu et al., 2006) and Zinc ions (Ishihara et al., 2003). In addition, another islet hormone 
somatostatin is reported to modulate glucagon secretion. Interestingly, glucagon itself is 
reported to regulate glucagon secretion. GLP-1 can suppress glucagon secretion directly and 
possibly indirectly by enhancing insulin secretion. 
4.1 Insulin 
Insulin, the major secretory product of ┚-cells, has been proposed as one of the intra-islet 
paracrine factors that can modulate the secretion of glucagon from neighboring ┙-cells 
(Asplin et al., 1981; Kawamori et al., 2009; Maruyama et al., 1984; Weir et al., 1976). 
Furthermore, proteins in the insulin signaling pathway are abundantly expressed in ┙-cells 
supporting an important role for insulin signaling in ┙-cells(Bhathena et al., 1982; Franklin 
et al., 2005; Patel et al., 1982). 
4.1.1 Modulation of glucagon secretion by insulin 
In clinical studies in human type 1 diabetes patients whose ┚-cell function is considered to 
be extinct (Asplin et al., 1981; Gerich et al., 1975), along with basic studies in insulinopenic 
animal models (Maruyama et al., 1984; Stagner and Samols, 1986; Weir et al., 1976), indicate 
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Schematic image for the ┚-cell-mediated suppression of glucagon secretion from ┙-cells via a 
paracrine mechanism. The ┚-cell secretes insulin, ┛-amino-butyric acid (GABA), and zinc 
irons (Zn) which suppress glucagon secretion. High glucose/hyperglycaemia suppresses 
glucagon secretion through the nervous system and by stimulation of ┚-cell secretion. 
Somatostatin also suppresses glucagon secretion. GLP-1 suppresses glucagon secretion 
through ┚-cell mediated and direct pathways. 
that insulin suppresses glucagon secretion in vivo. In insulinopenic animal models, 
exogenous insulin suppressed glucagon secretion (Greenbaum et al., 1991; Stagner and 
Samols, 1986; Weir et al., 1976). Conversely, suppression of insulin action by infusion of an 
anti-insulin antibody increased glucagon release (Maruyama et al., 1984). These studies 
clearly indicate the suppressive effect of insulin on glucagon secretion. Thus, it is 
conceivable that chronic and post-prandial hyperglucagonemia seen in diabetes patients 
(see section 2.4) is due to a lack of the direct suppression of insulin on glucagon secretion 
induced either by an absolute lack of insulin and/or ┙-cell insulin resistance(Meier et al., 
2006a; Raju and Cryer, 2005). 
In addition, insulin is reported to stimulate glucagon secretion through a “switch-off” 
mechanism (Hope et al., 2004; Zhou et al., 2004). During hypoglycemia, a decrease in 
intraislet insulin may act as a trigger for glucagon secretion as ┙-cells can sense the decrease 
in ambient insulin. This concept is proposed by studies wherein cessation of insulin 
administration in in vivo pancreas perfusion experiments in insulinopenic diabetic rats 
induces glucagon secretion in response to hypoglycemia (Hope et al., 2004; Zhou et al., 
2004). It is also possible that the defective secretory response of glucagon to hypoglycemia in 
diabetes patients occurs secondary to a defect in insulin sensing in -cells (see section 2.5). 
Thus, insulin is a center player not only in the suppression of glucagon secretion but also the 
stimulation of glucagon secretion. 
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4.1.2 Molecular mechanisms underlying the modulation of glucagon secretion by 
insulin signaling 
These in vivo reports suggest a direct effect of insulin in modulating glucagon secretion. On 
the other hand, recent in vitro studies in ┙-cell lines using gene knock-down techniques 
indicate a role for the insulin receptor and its signaling pathway in suppressing glucagon 
secretion by high glucose (Ravier and Rutter, 2005), as well as in stimulating glucagon 
secretion by low glucose concentration (Diao et al., 2005). 
The direct inhibitory effects of insulin to suppress glucagon secretion has been reported to 
occur either by 1) reducing the sensitivity of K+ATP channels (Franklin et al., 2005) which 
regulate glucagon secretion machinery via phosphatidyl inositol 3-kinase (PI3K) (Leung et 
al., 2006), or by 2) modulating Akt, a critical downstream effector of PI3K, leading to 
recruitment of the GABA-A receptor to the cellular membrane to allow its ligand, GABA, to 
inhibit glucagon secretion (see section 4.2) (Rorsman et al., 1989; Xu et al., 2006).  
4.1.3 The α-cell specific insulin receptor knockout mouse model 
While numerous reports indicate a pivotal role for insulin in the regulation of glucagon 
secretion, direct molecular evidence for the importance of insulin signaling in ┙-cells in vivo 
has been lacking until recently. The significance of systemic insulin signaling in glucose 
homeostasis is well known as insulin resistance is induced in insulin target organs including 
the liver, the skeletal muscle and the adipose tissues under diabetic state, and impacts on 
glycemic metabolism in these organs. Eventually, the genetic evidence of the in vivo 
significance of insulin signaling in ┙-cells in the regulation of glucagon secretion was 
provided by investigation of the ┙-cell specific insulin receptor knockout (┙IRKO) mice 
(Kawamori et al., 2009). 
The ┙IRKO mice exhibited glucose intolerance, hyperglycemia and hyperglucagonemia in 
the fed state together with enhanced glucagon secretion in response to L-arginine. These 
results indicate that disruption of insulin receptor in ┙-cells enhanced glucagon secretion by 
diminishing the glucagonostatic effect of insulin, and provided direct in vivo evidence for 
the suppression of glucagon secretion by insulin from ┚-cells through intra-islet paracrine 
manner. Interestingly, the mutant mice also displayed blunted glucagon response to 
hypoglycemia indicating a defective glucagon response through insulin “switch-off” 
mechanism (Hope et al., 2004; Zhou et al., 2004) by disruption of insulin signaling in ┙-cells. 
The results using ┙IRKO mice clearly demonstrate a critical role for insulin in the regulation 
of ┙-cell function in both normo- and hypoglycemic states in vivo. 
4.1.4 Model for the intraislet regulation of glucagon secretion from α-cells by insulin 
From these findings, a possible model for the intraislet regulation of glucagon secretion by 
insulin can be proposed. In states of hyperglycemia, the greater insulin secretion from ┚-
cells is stimulated and would activate insulin signaling in ┙-cells via paracrine manner, and 
represses glucagon secretion. On the other hand, in hypoglycemic state, the consequent 
levels of low insulin would allow the ┙-cells to sense the reduction in ambient insulin 
leading to a lack of activation of insulin signaling that in turn leads to the stimulation of 
glucagon secretion. This would occur in addition to possible direct stimulation by low 
glucose itself. Indeed, a recent clinical study reported that this proposed mechanism is 
actually feasible in humans (Cooperberg and Cryer, 2010). In this report, patients with type 
1 diabetes were subjected to normo- and hypoglycemic clamps and the effects of insulin 
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analogue glulisine were evaluated. Continuous glulisine infusion suppressed glucagon 
secretion both under normo- and hypoglycemic states, while discontinuation of glulisine 
infusion stimulated glucagon secretion in hypoglycemic state. From these studies, it is 
proposed that insulin overrides the effects of glucose and suppresses glucagon secretion in 
the hyperglycemic state, and decreasing insulin levels triggers glucagon response to 
hypoglycemia and precedes the direct effect of low glucose. 
 
 
In high glucose state, stimulated insulin secretion from ┚-cells acts on insulin receptor on the 
surface of ┙-cells then suppresses glucagon secretion by paracrine manner. In low glucose 
state, decreased insulin secretion from ┚-cells is recognized by ┙-cells as a reduction of 
insulin signaling in ┙-cells through insulin receptor, then ┙-cells increase glucagon secretion 
in response. 
4.2 GABA 
┛-amino-butyric acid (GABA) is produced from the excitatory amino acid glutamate by 
glutamic acid decarboxylase (GAD) and works as an important inhibitory neurotransmitter 
in neural synapses, mainly in the central nervous system (Kittler and Moss, 2003). In 
neurons, GABA is released by the presynaptic terminal into synaptic junctions and binds to 
GABA receptors on the postsynaptic membrane, inhibiting cellular electrical firing through 
modulation of ion channels and consequent membrane hyperpolarization (Kittler and Moss, 
2003). Islets are also innerved by GABA-ergic neurons (Sorenson et al., 1991), suggesting 
that GABA is a potential inhibitor of -cell function. 
In addition, GABA has also been reported to be secreted from ┚-cells and suppress glucagon 
secretion from ┙-cells in an intraislet paracrine manner (Rorsman et al., 1989; Wendt et al., 
2004; Xu et al., 2006). High glucose or glutamate levels stimulate secretion of GABA from ┚-
cells and the secreted GABA then binds to its receptor expressed on ┙-cells, inhibiting 
glucagon secretion through cellular membrane hyperpoloarization. Importantly, the GABA-
A receptor is recruited to the cellular membrane by insulin-Akt signaling (Xu et al., 2006), 
and its activation suppresses glucagon secretion through desensitization of K+ATP channels. 
These observations suggest a cooperative role between insulin and GABA in the inhibition 
of glucagon secretion. 
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4.3 Zinc 
Zinc ions (Zn2+), co-released with insulin by ┚-cells in response to high glucose levels, have 
been reported to activate K+ATP channels on ┙-cells, desensitize the channels and suppress 
glucagon secretion (Ishihara et al., 2003). Zn2+ is also reported to stimulate glucagon 
secretion from ┙-cells when its concentration falls as part of a “switch-off” mechanism 
(Zhou et al., 2007). However, another study reports a lack of inhibitory effect of exogenous 
Zn2+ on glucagon secretion (Ravier and Rutter, 2005), indicating that the effects of Zn2+ on 
glucagon secretion are complex and require further investigation. 
4.4 Somatostatin 
Somatostatin, an inhibitory hormone, secreted by neuronal and pancreatic ├-cells in islets 
inhibits both insulin and glucagon in a paracrine manner in the islet (Barden et al., 1977; 
Gerich et al., 1974; Starke et al., 1987). Somatostatin is considered to exert its suppressive 
effect on glucagon secretion largely through interstitial communication between ┙- and ├-
cells (Stagner and Samols, 1986). Following binding to its receptors on ┙-cells somatostatin 
inhibits glucagon secretion by inducing plasma membrane hyperpolarization (Yoshimoto et 
al., 1999), suppression of cAMP elevation (Schuit et al., 1989) and direct inhibition of the 
exocytotic machinery via a G-protein-dependent mechanism (Gromada et al., 2001). 
Somatostatin secretion from islet -cells is stimulated by glucose (Gerber et al., 1981; Honey 
et al., 1980), consistent with the report that the suppressive effect of high glucose on 
glucagon secretion may be mediated by glucose-induced secretion of somatostatin (Hauge-
Evans et al., 2009). Interestingly, global somatostatin knockout mice exhibit enhanced 
insulin and glucagon secretion in vivo and ex vivo. In addition the ability of exogenous 
glucose to suppress glucagon secretion is lost in islets isolated from somatostatin knockout 
mice (Hauge-Evans et al., 2009) and highlights the intra-islet interactions between 
somatostatin, glucagon, and insulin. These observations from a global knockout of 
somatostatin should be interpreted with caution since extra-pancreatic neuronal effects 
cannot be ruled out. It should also be noted that somatostatin involvement in glucagon 
suppression during hyperglycemia might be less important than the effects of ┚-cell 
secretion in vivo according to the direction of intraislet microcirculation, ┚-┙-├ (Gerich, 1990; 
Stagner and Samols, 1986). Interestingly, somatostatin is also reported to be involved in 
GLP-1 mediated suppression of glucagon secretion (see section 4.6). Further investigation is 
thus necessary to clarify the intra-islet relationship of islet hormones. 
4.5 Glucagon 
Interestingly, glucagon which is secreted by ┙-cells is reported to stimulate glucagon 
secretion (Ma et al., 2005). Upregulation of cAMP by glucagon signaling is suggested to 
stimulate glucagon exocytosis via a mechanism that is similar to the stimulatory effects of 
glucagon on insulin and somatostatin secretion (Huypens et al., 2000; Stagner et al., 1989). 
4.6 Glucagon like-peptide-1 (GLP-1) 
The incretin hormone, glucagon-like peptide-1 (GLP-1), is secreted by intestinal L-cells in 
response to food intake and is a strong stimulator of insulin secretion and also regulates ┚-
cell mass through modulation of cellular proliferation and death (Drucker, 2006). Therefore, 
GLP-1 contributes to glucose homeostasis acutely by enhancing ┚-cell secretory function and 
chronically by maintaining ┚-cell mass. In addition to these effects on ┚-cells, GLP-1 is 
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reported to suppress glucagon secretion by directly acting on ┙-cells or indirectly by 
stimulating insulin secretion or modulating other non-┚-cell hormones (e.g. somatostatin) 
which can in turn suppress glucagon secretion. However, the defects in GLP-1 secretion and 
action in type 2 diabetes likely impact the pathophysiology of the disease via abnormal 
regulation of both insulin and glucagon secretion (Holst et al., 2009). 
Paradoxically, another incretin hormone, glucose-dependent insulinotropic polypeptide 
(GIP), can stimulate glucagon secretion despite stimulating insulin secretion from ┚-cells in 
a manner similar to GLP-1 (de Heer et al., 2008; Meier et al., 2003; Pederson and Brown, 
1978). On the other hand, GLP-2, although derived from the same proglucagon gene as 
GLP-1, in intestinal L-cells, has not been reported to affect the secretory properties of -cells 
but stimulates glucagon secretion in human subjects (Meier et al., 2006b), by activation of 
GLP-2 receptors on ┙-cells (de Heer et al., 2007). 
4.6.1 Indirect suppression of glucagon secretion by GLP-1 
GLP-1 is reported to suppress glucagon secretion directly and/or indirectly through other 
cell-types; ┚- and ├-cells. In this point, many studies were conducted and displayed pros 
and cons to both theories. However, considering these reports comprehensively, it is less 
possible that only one mechanism is working in the suppressive effect of GLP-1 on 
glucagon, and it is conceivable that these direct and indirect manners are both regulating 
glucagon secretion with interacting each other. 
There are conflicting reports concerning the expression of GLP-1 receptors in ┙-cells (Heller 
et al., 1997; Moens et al., 1996). Previous studies investigating GLP-1 receptor expression in 
┙-cells by RNA expression and immunohistochemical analyses indicate that GLP-1 
receptors are not expressed in ┙-cells or if present are expressed at low levels (Tornehave et 
al., 2008), or by only a few ┙-cells (Heller et al., 1997). A recent study using in situ 
hybridization and immunofluorescence microscopy in mouse, rat, and human pancreas 
identified the islet cell types that express GLP-1 receptors (Tornehave et al., 2008) and 
concluded that GLP-1 receptors are not expressed in ┙-cells. Thus, it is unlikely that GLP-1 
can exert its direct effects on ┙-cells to impact glucagon secretion. On the other hand, GLP-1 
is a strong secretagogue for insulin from ┚-cells, and considering the central role for insulin 
in the regulation of glucagon secretion, it is reasonable to suggest that GLP-1 suppresses 
glucagon secretion by secreted insulin. GLP-1 is also reported to stimulate somatostatin 
secretion from ├-cells in response to high glucose (Orskov et al., 1988), and it is possible that 
the secreted somatostatin suppresses glucagon secretion (de Heer and Holst, 2007; Hauge-
Evans et al., 2009). This suggestion is supported by the observation that expression of a 
highly specific somatostatin receptor subtype 2 (SSTR2) antagonist completely abolished the 
GLP-1 effect on glucagon secretion in isolated perfused rat pancreas (de Heer et al., 2008). 
However, considering that the direction of intra-islet microcirculation occurs from the core 
of islets to the mantle; from ┚-┙-├ at least in rodents (Stagner and Samols, 1986), additional 
studies are necessary to explore these possibilities. 
4.6.2 Direct suppression of glucagon secretion by GLP-1 
In contrast, reports that GLP-1 (Creutzfeldt et al., 1996) and DPP-4 inhibitor (Foley et al., 
2008) treatment suppressed excessive glucagon secretion in type 1 diabetes patients even in 
the absence of secretory products from ┚-cells, suggest a potential direct effect of GLP-1 on 
glucagon suppression. A recent study by De Marinis et al reported that the expression of 
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GLP-1 receptors in ┙-cells is less than 0.2 % of its expression in ┚-cells, and consequently 
GLP-1 can induce a small elevation in cAMP activating PKA followed by selective inhibition 
of N-type Ca2+ ion channels, thus suppressing glucagon exocytosis (De Marinis et al.). In 
contrast, receptors for epinephrine or GIP are expressed abundantly in ┙-cells, and these 
molecules stimulate electrical activity significantly leading to an increase in Ca2+ in ┙-cells, 
causing glucagon exocytosis to accelerate through activation of L-type Ca2+ ion channels (De 
Marinis et al.). Studies using isolated islets indicated that GLP-1 effect on glucagon 
suppression is independent of insulin and intra-islet paracrine effect. 
4.6.3 Model for the GLP-1 mediated suppression of glucagon secretion 
Considering these reports together, it is possible that GLP-1 suppresses glucagon secretion 
directly, but in postprandial state, GLP-1 enhances insulin secretion from ┚-cells together 
with another incretin GIP, and subsequently exerts suppressive effects on glucagon 
secretion. Further urgent investigations are necessary to understand the effects of GLP-1 on 
┙-cell function. However, reports of GLP-1 induced suppression of glucagon secretion, in 
addition to its beneficial role on ┚-cells including augmentation of glucose-stimulated 
insulin secretion, promotion of ┚-cell proliferation, and protection of ┚-cells from various 
cytotoxicities, emphasizes the potential of GLP-1 therapy for the treatment of diabetes. 
 
 
 
 
GLP-1 directly suppresses glucagon secretion from ┙-cells through slight increase of cAMP 
followed by inhibition of N-type Ca2+ channels (De Marinis, 2010) (57). GLP-1 also potentiates 
insulin secretion from ┚-cells then suppresses glucagon secretion through insulin effects on ┙-
cells. Glucose stimulates insulin secretion from ┚-cells and suppresses glucagon from ┙-cells 
through insulin effects, while glucose can stimulate glucagon secretion from ┙-cells. 
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5. Conclusion and future perspectives 
While glucagon was believed to elevate or decline simply in response to blood glucose 
levels, emerging work reveals a complex but sophisticated regulatory mechanism for the 
modulation of glucagon output from the ┙-cells with effects from pancreatic and endocrine 
hormones including insulin, somatostatin, epinephrine and incretins, nutrients and central 
and autonomic nervous pathways. The concept of intra-islet regulation of glucagon 
secretion that is mediated by insulin in a paracrine manner is now recognized as an 
important pathway that determines ┙-cell functions. Thus, disorder in intra-islet regulation 
of glucagon secretion is deeply involved in pathophysiology of diabetes. Considering that 
the diabetic state is characterized by systemic insulin resistance, that includes non-classical 
targets such as ┚-cells (Gunton et al., 2005; Kulkarni et al., 1999), it would be important to 
explore whether insulin resistance at the level of the ┙-cell underlies some of the early 
defects that lead to enhanced glucagon output and a consequent defect in glucose 
homeostasis. 
Recently, new therapeutic approaches targeting excessive glucagon by suppression of 
glucagon secretion or inhibition of glucagon receptors and their function were tried in the 
treatment of diabetes, but simple inhibition of glucagon effect does not result in 
improvement of glucose homeostasis because of hypoglycemia by lack of glucagon effect. In 
future therapy in diabetes, we need to aim glucagon to work appropriately and rest 
properly, then improve its effects on other organs and hormonal balance between glucagon 
and insulin. Further studies are necessary to explore whether cells in the central and/or 
autonomic nervous systems can be targeted to modulate glucagon secretion for therapeutic 
purposes. 
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